Abstract | OBJECTIVE: Vasomotor symptoms (VMS) may be a marker of cardiovascular risk. We aimed to evaluate the cross-sectional association of VMS presence and severity with hemostatic parameter levels measured at baseline among Women's Health Initiative (WHI) Hormone Therapy trial postmenopausal participants. METHODS: This cross-sectional analysis included 2,148 postmenopausal women with measures of VMS presence and severity reported in the 4 weeks before WHI baseline, who were not using warfarin or hormone therapy and for whom the following baseline hemostatic parameters were measured within the WHI Cardiovascular Disease Biomarker Case-Control Study: antithrombin, plasminogen activator inhibitor-1, protein C antigen, total and free protein S antigen, total and free tissue factor pathway inhibitor, D-dimer, normalized activated protein C sensitivity ratio, and thrombin generation. Using multiple linear regression, we estimated the adjusted average difference in each hemostatic parameter associated with VMS presence and severity. A multiple comparisons-corrected P value was computed using the P-min procedure to determine statistical significance of our smallest observed P value. RESULTS: Women were 67 years of age on average and 33% reported VMS presence at baseline. There was some suggestion that VMS presence may be associated with a -0.34 adjusted difference in normalized activated protein C sensitivity ratio compared with no VMS (95% CI, -0.60 to -0.087; Pā=ā0.009), but this association was not significant after correction for multiple comparisons (Pā=ā0.073). VMS presence or severity was not significantly associated with the other hemostatic parameters. CONCLUSIONS: We found no convincing evidence that VMS presence or severity was associated with levels of hemostatic parameters among postmenopausal women.
|
Authors | Laura B Harrington, Marc Blondon, Mary Cushman, Andrew M Kaunitz, Jacques E Rossouw, Matthew A Allison, Lisa W Martin, Karen C Johnson, Jan Rosing, Nancy F Woods, Andrea Z LaCroix, Susan R Heckbert, Barbara McKnight, Nicholas L Smith |
Journal | Menopause (New York, N.Y.)
(Menopause)
Vol. 24
Issue 4
Pg. 360-370
(04 2017)
ISSN: 1530-0374 [Electronic] United States |
PMID | 27922933
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antigens
- Antithrombin Proteins
- Fibrin Fibrinogen Degradation Products
- Lipoproteins
- Plasminogen Activator Inhibitor 1
- Protein C
- Protein S
- fibrin fragment D
- lipoprotein-associated coagulation inhibitor
- Thrombin
|
Topics |
- Aged
- Antigens
(blood)
- Antithrombin Proteins
(metabolism)
- Cross-Sectional Studies
- Female
- Fibrin Fibrinogen Degradation Products
(metabolism)
- Hemostasis
- Hot Flashes
(blood)
- Humans
- Lipoproteins
(blood)
- Middle Aged
- Plasminogen Activator Inhibitor 1
(blood)
- Postmenopause
(blood)
- Protein C
(immunology)
- Protein S
(immunology)
- Severity of Illness Index
- Sweating
- Symptom Assessment
- Thrombin
(biosynthesis)
|